5-(4-Bromophenyl)-4,6-dichloropyrimidine for Pharmaceutical Intermediate

Pharmaceutical Intermediates 5-(4-Bromophenyl)-4,6-dichloropyrimidine CAS 146533-41-7 The trade name of macitentan is opsumit. It is an oral dual antagonist of ETA and ETB developed by actelionpharm, Switzerland. In October 2013, it was approved by FDA for the treatment of pulmonary chemicalbook hypertension, pulmonary fibrosis and other diseases. Since the listing of the commodity, its effectiveness, safety and tolerance have been good, and the market prospect is promising. 5 -...